HRP20130976T1 - Karbonilaminopirolopirazoli, potentni inhibitori kinaza - Google Patents
Karbonilaminopirolopirazoli, potentni inhibitori kinaza Download PDFInfo
- Publication number
- HRP20130976T1 HRP20130976T1 HRP20130976TT HRP20130976T HRP20130976T1 HR P20130976 T1 HRP20130976 T1 HR P20130976T1 HR P20130976T T HRP20130976T T HR P20130976TT HR P20130976 T HRP20130976 T HR P20130976T HR P20130976 T1 HRP20130976 T1 HR P20130976T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- image
- treatment
- Prior art date
Links
- XPBFIMLMVNXIIB-UHFFFAOYSA-N 3-isocyanatopyrrolo[3,2-c]pyrazole Chemical class N1=CC=C2N=NC(N=C=O)=C21 XPBFIMLMVNXIIB-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (8)
1. Spoj formule III,
[image]
,
naznačen time što:
B je -O;
R1 se bira između C1-C8 alkila, 3-10-eročlanog heterociklila, gdje je R1 izborno dodatno supstituiran s 1-6 skupina, koje se bira između -halogenida, -hidroksila, -CN, C1-C3 alkila, C1-C3 perfluoralkila, C1-C3 alkoksila, -NH2, -(C1-C3 alkilamino);
svaki R2 je metil i R3 je metil,
R8 se bira između -CH2-N-(CH3)2, -CH2-NH-CH3 i -CH2-NH2; i
R9 je fenil,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine
[image]
i
[image]
,
ili njihove farmaceutski prihvatljive soli.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine
[image]
i
[image]
,
ili njihove farmaceutski prihvatljive soli.
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivu podlogu.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi kao medikament.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju abnormalnog staničnog rasta kod sisavca.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen proizvodnji medikamenta za liječenje abnormalnog staničnog rasta kod sisavca.
8. Kombinacija spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegove farmaceutski prihvatljive soli, s jednom ili više tvari, koje se bira između antitumorskih sredstava, antiangiogenetskih sredstava, inhibitora prijenosa signala i antiproliferativnih sredstva, naznačena time što je namijenjena upotrebi u liječenju abnormalnog staničnog rasta kod sisavca.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75334905P | 2005-12-21 | 2005-12-21 | |
| US86493206P | 2006-11-08 | 2006-11-08 | |
| PCT/IB2006/003646 WO2007072153A2 (en) | 2005-12-21 | 2006-12-12 | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130976T1 true HRP20130976T1 (hr) | 2013-11-22 |
Family
ID=38189022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130976TT HRP20130976T1 (hr) | 2005-12-21 | 2013-10-15 | Karbonilaminopirolopirazoli, potentni inhibitori kinaza |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7884117B2 (hr) |
| EP (1) | EP1979356B1 (hr) |
| JP (1) | JP4635089B2 (hr) |
| KR (1) | KR101029167B1 (hr) |
| AP (1) | AP2369A (hr) |
| AU (1) | AU2006327866B2 (hr) |
| BR (1) | BRPI0620354A2 (hr) |
| CA (1) | CA2634381C (hr) |
| CR (1) | CR10094A (hr) |
| CU (1) | CU23751B7 (hr) |
| DK (1) | DK1979356T3 (hr) |
| EA (1) | EA015513B1 (hr) |
| EC (1) | ECSP088558A (hr) |
| ES (1) | ES2435405T3 (hr) |
| GE (1) | GEP20104974B (hr) |
| HK (1) | HK1128290A1 (hr) |
| HR (1) | HRP20130976T1 (hr) |
| IL (1) | IL191776A (hr) |
| MA (1) | MA30076B1 (hr) |
| ME (1) | ME00006B (hr) |
| MY (1) | MY151455A (hr) |
| NO (1) | NO20082482L (hr) |
| NZ (1) | NZ568692A (hr) |
| PL (1) | PL1979356T3 (hr) |
| PT (1) | PT1979356E (hr) |
| RS (2) | RS53029B (hr) |
| WO (1) | WO2007072153A2 (hr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL385265A1 (pl) * | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej |
| EP2370451B1 (en) | 2008-12-02 | 2016-11-16 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
| KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
| EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US10428019B2 (en) * | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| RU2013126036A (ru) | 2010-11-17 | 2014-12-27 | Ф. Хоффманн-Ля Рош Аг | Способ лечения опухолей |
| US8771682B2 (en) | 2011-04-26 | 2014-07-08 | Technische Universtität Dresden | Methods and compositions for reducing interleukin-4 or interleukin-13 signaling |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| KR20140135198A (ko) | 2012-03-16 | 2014-11-25 | 에프. 호프만-라 로슈 아게 | Pak1 억제제로 흑색종을 치료하는 방법 |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| SG10201912897UA (en) | 2014-01-16 | 2020-02-27 | Wave Life Sciences Ltd | Chiral design |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| KR102575327B1 (ko) | 2014-10-31 | 2023-09-07 | 유비이 가부시키가이샤 | 치환 디히드로피롤로피라졸 화합물 |
| JP6854762B2 (ja) * | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US10273252B2 (en) | 2015-06-15 | 2019-04-30 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017144546A1 (en) | 2016-02-23 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma |
| WO2020100944A1 (ja) | 2018-11-14 | 2020-05-22 | 宇部興産株式会社 | ジヒドロピロロピラゾール誘導体 |
| WO2020140098A1 (en) * | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP3956446A1 (en) | 2019-04-17 | 2022-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1320531T3 (da) * | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse |
| US20060135508A1 (en) | 2002-07-25 | 2006-06-22 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| GB0229526D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| EP1668013B1 (en) * | 2003-09-23 | 2012-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
| BRPI0518509A2 (pt) | 2005-01-10 | 2008-11-25 | Pfizer | pirrolopirazàis, inibidores de cinase potentes |
-
2006
- 2006-12-12 DK DK06831731.2T patent/DK1979356T3/da active
- 2006-12-12 WO PCT/IB2006/003646 patent/WO2007072153A2/en active Application Filing
- 2006-12-12 MY MYPI20082267 patent/MY151455A/en unknown
- 2006-12-12 AU AU2006327866A patent/AU2006327866B2/en not_active Ceased
- 2006-12-12 ME MEP-2008-8A patent/ME00006B/me unknown
- 2006-12-12 BR BRPI0620354-0A patent/BRPI0620354A2/pt not_active IP Right Cessation
- 2006-12-12 KR KR1020087014963A patent/KR101029167B1/ko not_active IP Right Cessation
- 2006-12-12 PL PL06831731T patent/PL1979356T3/pl unknown
- 2006-12-12 JP JP2008546667A patent/JP4635089B2/ja not_active Expired - Fee Related
- 2006-12-12 CA CA2634381A patent/CA2634381C/en not_active Expired - Fee Related
- 2006-12-12 EA EA200801291A patent/EA015513B1/ru not_active IP Right Cessation
- 2006-12-12 GE GEAP200610777A patent/GEP20104974B/en unknown
- 2006-12-12 ES ES06831731T patent/ES2435405T3/es active Active
- 2006-12-12 NZ NZ568692A patent/NZ568692A/en not_active IP Right Cessation
- 2006-12-12 AP AP2008004506A patent/AP2369A/xx active
- 2006-12-12 PT PT68317312T patent/PT1979356E/pt unknown
- 2006-12-12 RS RS20130498A patent/RS53029B/en unknown
- 2006-12-12 EP EP06831731.2A patent/EP1979356B1/en active Active
- 2006-12-12 RS RSP-2008/0281A patent/RS20080281A/sr unknown
- 2006-12-12 US US12/158,241 patent/US7884117B2/en not_active Expired - Fee Related
-
2008
- 2008-05-27 IL IL191776A patent/IL191776A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082482A patent/NO20082482L/no not_active Application Discontinuation
- 2008-06-18 EC EC2008008558A patent/ECSP088558A/es unknown
- 2008-06-19 CU CU20080115A patent/CU23751B7/es active IP Right Grant
- 2008-06-20 CR CR10094A patent/CR10094A/es unknown
- 2008-06-20 MA MA31060A patent/MA30076B1/fr unknown
-
2009
- 2009-07-06 HK HK09106049.9A patent/HK1128290A1/xx not_active IP Right Cessation
-
2013
- 2013-10-15 HR HRP20130976TT patent/HRP20130976T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| HRP20180202T1 (hr) | Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20211617T1 (hr) | Benzo[b]tiofenski spojevi kao agonisti sting | |
| HRP20161428T1 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| HRP20110841T1 (hr) | Korisni monobaktamski antibiotici | |
| RS52953B (en) | PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| WO2008042240A3 (en) | Enantiomerically pure phosphoindoles as hiv inhibitors | |
| RS52245B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| HRP20140501T1 (hr) | Derivati benzazepina korisni kao antagonisti vazopresina | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| EA201391325A1 (ru) | Новые производные цефалоспорина и их фармацевтические композиции | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| RU2015140387A (ru) | Пиридопиримидиновое или пиримидопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений | |
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A |